Abstract
Pentraxin 3 (PTX3), an acute phase protein, contrary to C-reactive protein (CRP), is produced locally, where the inflammation takes place, for example in the endothelium. It is not clearly known whether the inflammatory factors are the cause of atherosclerosis or only indicators of vascular inflammation. It is still not known what is the role of PTX in the natural history of atherosclerosis — protection or promotion. It was established that the elevated plasma concentration of PTX is related to the occurrence of cardiovascular events caused by atherosclerosis, including myocardial infarction (MI), decreased 3-months survival after MI, unstable angina or heart failure. On the other hand, PTX is suspected to play a protective role in the ischemic cardiac muscle. Therefore, if confirmed in trials, PTX3 could be administered during acute coronary syndrome. PTX3 might in the future become useful in assessing prognosis for patients with cardiovascular diseases and choosing the best therapeutic option for them.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
